The combined portfolios were up by £3,350 on the week at the end of play yesterday, but drops in both IQE:IQE and OPTI:Optibiotix today have wiped out a significant proportion of those gains. The portfolios still ended healthily up by £1,919 with a £8,993 buffer between value and cost, but the overall value dropped to £79,270 which is back under the £80,000 milestone I was hoping to pass in today's snapshot.
Worst performer by a mile was IKA:Ilika. This really has been a disaster - dropping 15% this week and now down by 60% and losing £337. I was foolish enough to buy the story without looking at the Board of Directors. Close examination would have revealed a bunch of scientists without a clue how to commercialise anything. They have invented a fantastic battery - shame they haven't sold any! The management here reminds me of TRK:Torotrak and I believe the company will go the same way unless they appoint a Commercial Director.
OPTI:Optibiotix had even more amazing news this week, sealing a new deal with Tata Chemicals. Frustratingly the share price only finished the week up by 1p. Better than being down, but with a distinct air of damp squib.
SBTX:SkinBioTherapeutics did much better than its parent company, climbing 11% probably on the back of the successful OPTI:Optibiotix deals improving confidence that this company can do the same. These are only 12% down on my purchase price now so could be back in profit soon.
Need I say what wins Share of the Week? IQE:IQE climbed 44% in my ISA despite the share price plunging 12% immediately after interims were published. That 12% drop would have been a reduction against my purchase price of 100% in my ISA, as it matched the price I paid for the shares. I bought some in my SIPP that morning, tragically not at the bottom of the dip, but enough that I made a gain of £334 (14%) in 4 days.
The cash was re-invested so cost goes back to where it was, and the gap gets even wider.
The ISA and share portfolios looks like this
| Weekly Change | |||
| Cash | £43.34 | -£2,403.75 | |
| Portfolio cost | £44,426.84 | +£0 | |
| Portfolio sell value (bid price - commission) | £49,812.24 | (+12.1%) | +£1,430.10 |
| Potential profits | £10,659.94 | +£1,298.33 | |
| Yr 3 Dividends | £0 | +£0 | |
| Yr 3 Profit from sales | £585.38 | +£0 | |
| Yr 3 Average monthly cash profit | £465.06 | (12.6%) | -£120.32 |
| Total Dividends | £1,179.05 | +£0 | |
| Total Profit from sales | £7,297.85 | +£0 | |
| Average monthly cash profit | £332.67 | (9.0%) | -£3.23 |
| (Sold stocks profit + Dividends - Fees / Months) |
All the cash was moved out to the SIPP, or used for the monthly ISA fee, and the value increased by £1,430 mainly thanks to IQE:IQE with a little help from elsewhere. Nearly all the gains were profit, with SBTX:Skinbiotherapeutics reducing the losses with a nice rise.
The green line has dipped because the cash was removed from the account to the SIPP, but the gap remains wonderful
The SIPP looks like this after week 93
| Weekly Change | |||
| Cash | £20.92 | +£0.35 | |
| Portfolio cost | £25,218.51 | +£2,389.88 | |
| Portfolio sell value (bid price - commission) | £28,994.78 | (15%) | +£503.10 |
| Potential profits | £4,781.16 | +£499.21 | |
| Yr 2 Dividends | £294.96 | +£0 | |
| Yr 2 Profit from sales | £6,575.33 | +£0 | |
| Yr 2 Average monthly cash profit | £718.09 | (34.2%) | -£19.02 |
| Total Dividends | £708.15 | +£0 | |
| Total Profit from sales | £8,925.19 | +£0 | |
| Average monthly cash profit | £442.96 | (21.1%) | -£5.28 |
| (Sold stocks profit + Dividends - Fees / Months) |
Big increase in cost from the IQE:IQE purchase and increase in profits thanks to IQE:IQE and a little from OPTI:Optibiotix. LGEN:Legal & General had a bad week which meant the profits weren't as high as they could have been.
Great smashing super
The trading account looks terrible after week 59
| Weekly Change | |||
| Cash | £79.63 | +£0 | |
| Portfolio cost | £486.05 | +£0 | |
| Portfolio sell value (bid price - commission) | £316.09 | (-34.8%) | -£13.90 |
| Potential profits | £0 | +£0 | |
| Dividends | £1.15 | +£0 | |
| Profit from sales | -£22.85 | +£0 | |
| Average monthly cash profit | -£1.59 | (-3.9%) | +£0.03 |
| (Sold stocks profit + Dividends - Fees / Months) |
REDS:RedstoneConnect put out a bloody awful trading statement. There was no bad news - but there was no news either. They may as well have not bothered for all the information it provided, and the share price reacted accordingly and is even worse than it's been for the last few months. This has been a very harsh lesson on the importance of ignoring bulletin board hype as I fell for it hook, line, sinker and copy of the Angling Times!
Not great, smashing or super
Next Tuesday sees the likely launch of the iPhone 8 and all the associated hype that could support the scarily high IQE:IQE share price. That support was distinctly lacking today though. No other news expected but who knows what will come?
No comments:
Post a Comment